# Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression

> **NCT04923204** · — · COMPLETED · sponsor: **AB Biotics, SA** · enrollment: 76 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DIAGNOSTIC_TEST:** Pharmacogenomic-testing with NEUROPHARMAGEN

## Key facts

- **NCT ID:** NCT04923204
- **Lead sponsor:** AB Biotics, SA
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-01
- **Primary completion:** 2016-03-31
- **Final completion:** 2019-12-05
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2021-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04923204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04923204, "Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04923204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*